Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Docosahexaenoic Acid Clear all
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 4, 2026, 7:36 AM EDT
Completed No phase listed Observational

PET Imaging of DHA Metabolism

NCT00074503
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

NCT00211562
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Omega 3, Vitamin E+C
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

NCT00970489
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Omega -3 fatty acids, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

NCT02670382
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
EPA, DHA, sunflower oil
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 4, 2026, 7:36 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL

NCT01696435
View directory record Official record
Conditions
Depression, Depressive Symptoms, Mood
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Fish oil placebo, Vitamin D placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
18,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

NCT00243867
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Taxoprexin, Carboplatin, Paclitaxel
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 4, 2026, 7:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega-3 Fatty Acids in Sickle Cell Disease

NCT02947100
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCD-Omegatex™
Drug
Lead sponsor
Robin E. Miller
Other
Eligibility
8 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health

NCT05295719
View directory record Official record
Conditions
Obesity, Inflammation, Human Microbiome, Insulin Resistance, Dyslipidemias
Interventions
Omega-3 polyunsaturated fatty acid, High-Intensity Interval Training, Safflower oil, Low-intensity training
Dietary Supplement · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 4, 2026, 7:36 AM EDT
Recruiting Not applicable Interventional

OMEGA - Dietary Intervention - COPD Trial

NCT05297279
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
Home delivery Omega-3 rich Food, Dietary Motivational Coaching, Home delivery Food
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Early Phase 1 Interventional

Window of Opportunity Study Targeting the Inflammatory Milieu

NCT01881048
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Omega-3 fatty acid, Celecoxib
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression

NCT00361374
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
eicosapentaenoic acid, docosahexaenoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Dietary Intervention for Bipolar Disorder

NCT02272010
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Experimental Diet, Comparator Diet
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 4, 2026, 7:36 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389
View directory record Official record
Conditions
Depression, Depression, Postpartum
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo
Drug · Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

NCT02133664
View directory record Official record
Conditions
Multiple Sclerosis, Cognition
Interventions
lipoic acid and omega-3 fatty acids, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

NCT01838239
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Healthy Subjects
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 4, 2026, 7:36 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 4, 2026, 7:36 AM EDT